Glioblastoma chemoattract migratory interneuron precursors modified to deliver therapeutic proteins
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Glioblastoma has a poor prognosis with limited therapeutic options, in part due to the presence of the blood brain barrier, which often prevents the delivery of therapeutic agents, and the immune suppressive tumor environment (TME), which is a challenge for T-cell based immunotherapies. We developed a cellular delivery vector where implanted modified post-mitotic Migratory Inhibitory Interneuron Precursors (MIPs) are chemoattracted to high-grade glioma (HGG), independent of expressed antigens and unhindered by the TME, to deliver therapeutic proteins of choice.
